The levonorgestrel-releasing intrauterine system for endometrial protection during estrogen replacement therapy: A clinical review

Climacteric

Volumn 18, Issue 4, 2015, Pages 470-482

  Depypere, H ^a   Inki, P ^b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b BAYER PHARMA AG   (Germany)

Author keywords

efficacy; endometrial protection; estrogen replacement therapy; Levonorgestrel releasing intrauterine system; menopause; menstrual bleeding profile; safety

Indexed keywords

ESTROGEN; GESTAGEN; LEVONORGESTREL; CONTRACEPTIVE AGENT;

BREAST CANCER; CLIMACTERIUM; CLINICAL EFFECTIVENESS; CONTRACEPTIVE BEHAVIOR; DRUG METABOLISM; ENDOMETRIUM CANCER; ENDOMETRIUM PROTECTION; ESTROGEN THERAPY; HUMAN; LEVONORGESTREL RELEASING INTRAUTERINE SYSTEM; MENOPAUSAL SYNDROME; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); OVARY CANCER; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE; PRIORITY JOURNAL; PROTECTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; UTERINE BLEEDING PATTERN; ADVERSE EFFECTS; CHEMICALLY INDUCED; ENDOMETRIAL HYPERPLASIA; FEMALE; INTRAUTERINE CONTRACEPTIVE DEVICE; MIDDLE AGED; PATIENT ATTITUDE;

CONTRACEPTIVE AGENTS, FEMALE; ENDOMETRIAL HYPERPLASIA; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PERIMENOPAUSE; POSTMENOPAUSE; QUALITY OF LIFE;

EID: 84932096982     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2014.991302     Document Type: Review

References (50)

1. de Villiers TJ, Gass ML, Haines CJ, et al. Global consensus statement on menopausal hormone therapy. Climacteric 2013; 16: 203-4
2. Furness S, Roberts H, Marjoribanks J, Lethaby A. H ormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev 2012; 8: CD000402
3. Mirena Product Monograph. Bayer HealthCare, 2012. Available at: http://www.mirena.com/html/pdf/Mirena-Product-Monograph- low-res-20120223-670.pdf. Last accessed 22 May 2014
4. Hubacher D, Grimes D A. N oncontraceptive health benefits of intrauterine devices: A systematic review. Obstet Gynecol Surv 2002; 57: 120-8
5. Sitruk-Ware R. R outes of delivery for progesterone and progestins. Maturitas 2007; 57: 77-80
6. Allen RH, Cwiak CA, Kaunitz AM. Contraception in women over 40 years of age. CMAJ 2013; 185: 565-73
7. Baldwin M K, Jensen J T. C ontraception during the perimenopause. Maturitas 2013; 76: 235-42
8. Long M E, Faubion S S, Maclaughlin K L, et a l. C ontraception and hormonal management in the perimenopause. J Womens Health (Larchmt) 2014 April 28. Epub ahead of print
9. US Selected Practice Recommendations for Contraceptive Use, 2013. US Department of Health and Human Services Centers for Disease Control and Prevention, 2013. Available at: http://www. cdc.gov/mmwr/pdf/rr/rr6205.pdf. Last accessed 21 May 2014
10. Hale G E, Manconi F, Luscombe G, Fraser I S. Q uantitative measurements of menstrual blood loss in ovulatory and anovulatory cycles in middle-and late-reproductive age and the menopausal transition. Obstet Gynecol 2010; 115: 249-56
11. Hickey M, Ambekar M. Abnormal bleeding in postmenopausal hormone users-What do we know today? Maturitas 2009; 63: 45-50
12. Antoniou G, Kalogirou D, Karakitsos P, et al. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints versus estradiol-releasing vaginal ring with a vaginal progesterone suppository: clinical and endometrial responses. Maturitas 1997; 26: 103-11
13. Kalogirou D, Antoniou G, Karakitsos P, et al. A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response. Int J Fertil Menopausal Stud 1996; 41: 522-7
14. Suvanto-Luukkonen E, Kauppila A. T he levonorgestrel intrauterine system in menopausal hormone replacement therapy: five-year experience. Fertil Steril 1999; 72: 161-3
15. S uvanto-Luukkonen E, Malinen H, Sundstrom H, et al. E ndometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone. Acta Obstet Gynecol Scand 1998; 77: 758-63
16. Ewies A A, Alfhaily F. Use of levonorgestrel-releasing intrauterine system in the prevention and treatment of endometrial hyperplasia. Obstet Gynecol Surv 2012; 67: 726-33
17. Somboonporn W, Panna S, Temtanakitpaisan T, et al. Effects of the levonorgestrel-releasing intrauterine system plus estrogen therapy in perimenopausal and postmenopausal women: systematic review and meta-analysis. Menopause 2011; 18: 1060-6
18. Raudaskoski T, Tapanainen J, Tomas E, et al. Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response. Bjog 2002; 109: 136-44
19. Suhonen SP, Holmstrom T, Allonen HO, Lahteenmaki P. Intrauterine and subdermal progestin administration in postmenopausal hormone replacement therapy. Fertil Steril 1995; 63: 336-42
20. Suhonen S, Haukkamaa M, Holmstrom T, et al. Endometrial response to hormone replacement therapy as assessed by expression of insulin-like growth factor-binding protein-1 in the endometrium. Fertil Steril 1996; 65: 776-82
21. Suvanto-Luukkonen E, Sundstrom H, Penttinen J, et al. Insulinlike growth factor-binding protein-1: A biochemical marker of endometrial response to progestin during hormone replacement therapy. Maturitas 1995; 22: 255-62
22. Hampton NR, Rees MC, Lowe DG, et al. Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: A successful regimen for HRT in perimenopausal women. Hum Reprod 2005; 20: 2653-60
23. Kupperman HS, Blatt MH, Wiesbader H, Filler W. Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrheal indices. J Clin Endocrinol Metab 1953; 13: 688-703
24. Kupperman H S, Wetchler B B, Blatt M H. C ontemporary therapy of the menopausal syndrome. J Am Med Assoc 1959; 171: 1627-37
25. Raudaskoski T H, Lahti E I, Kauppila A J, et al. T ransdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses. Am J Obstet Gynecol 1995; 172: 114-19
26. Suvanto-Luukkonen E, Sundstrom H, Penttinen J, et a l. Percutaneous estradiol gel with an intrauterine levonorgestrel releasing device or natural progesterone in hormone replacement therapy. Maturitas 1997; 26: 211-17
27. Pirimoglu ZM, Ozyapi A G, Kars B, et al. C omparing the effects of intrauterine progestin system and oral progestin on healthrelated quality of life and Kupperman index in hormone replacement therapy. J Obstet Gynaecol Res 2011; 37: 1376-81
28. Depypere H T, Hillard T, Erkkola R, et al. A 60-month noncomparative study on bleeding profiles with the levonorgestrel intrauterine system from the late transition period to estrogen supplemented menopause. Eur J Obstet Gynecol Reprod Biol 2010; 153: 176-80
29. Suhonen S, Holmstrom T, Lahteenmaki P. Three-year follow-up of the use of a levonorgestrel-releasing intrauterine system in hormone replacement therapy. Acta Obstet Gynecol Scand 1997; 76: 145-50
30. Boon J, Scholten PC, Oldenhave A, Heintz AP. Continuous intrauterine compared with cyclic oral progestin administration in perimenopausal HRT. Maturitas 2003; 46: 69-77
31. Merz E, Miric-Tesanic D, Bahlmann F, et al. S onographic size of uterus and ovaries in pre-and postmenopausal women. Ultrasound Obstet Gynecol 1996; 7: 38-42
32. Sokalska A, Valentin L. Changes in ultrasound morphology of the uterus and ovaries during the menopausal transition and early postmenopause: A 4-year longitudinal study. Ultrasound Obstet Gynecol 2008; 31: 210-17
33. Varila E, Wahlstrom T, Rauramo I. A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. Fertil Steril 2001; 76: 969-73
34. Raudaskoski TH, Tomas EI, Paakkari IA, et al. Serum lipids and lipoproteins in postmenopausal women receiving transdermal oestrogen in combination with a levonorgestrel-releasing intrauterine device. Maturitas 1995; 22: 47-53
35. Suvanto-Luukkonen E, Sundstrom H, Penttinen J, Kauppila A. Lipid effects of an intrauterine levonorgestrel device or oral vs. vaginal natural progesterone in post-menopausal women treated with percutaneous estradiol. Arch Gynecol Obstet 1998; 261: 201-8
36. Canonico M, Oger E, Conard J, et al. Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study. J Thromb Haemost 2006; 4: 1259-65
37. Scarabin P Y, Oger E, Plu-Bureau G, et al. D ifferential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003; 362: 428-32
38. Lidegaard O, Nielsen LH, Skovlund CW, Lokkegaard E. Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10. BMJ 2012; 344: e2990
39. Blumenfeld Z, Boulman N, Leiba R, et al. H igh C-reactive protein levels are associated with oral hormonal menopausal therapy but not with intrauterine levonorgestrel and transdermal estradiol. Scand J Clin Lab Invest 2007; 67: 257-63
40. Lyytinen H K, Dyba T, Ylikorkala O, Pukkala E I. A case-control study on hormone therapy as a risk factor for breast cancer in Finland: Intrauterine system carries a risk as well. Int J Cancer 2010; 126: 483-9
41. Dinger J, Bardenheuer K, Minh T D. L evonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer. Contraception 2011; 83: 211-17
42. Koskela-Niska V, Pukkala E, Lyytinen H, et a l. E ffect of various forms of postmenopausal hormone therapy on the risk of ovarian cancer- A population-based case control study from Finland. Int J Cancer 2013; 133: 1680-8
43. Jaakkola S, Lyytinen HK, Dyba T, et al. Endometrial cancer associated with various forms of postmenopausal hormone therapy: A case control study. Int J Cancer 2011; 128: 1644-51
44. Soini T, Hurskainen R, Grenman S, et al. Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland. Obstet Gynecol 2014; 124: 292-9
45. Hunter MS. T he Women's Health Questionnaire (WHQ): Frequently asked questions (FAQ). Health Qual Life Outcomes 2003; 1: 41
46. Kailasam C, Cahill D. R eview of the safety, efficacy and patient acceptability of the levonorgestrel-releasing intrauterine system. Patient Prefer Adherence 2008; 2: 293-302
47. Nelson A, Apter D, Hauck B, et al. Two low-dose levonorgestrel intrauterine contraceptive systems: A randomized controlled trial. Obstet Gynecol 2013; 122: 1205-13
48. Suhonen SP, Allonen HO, Lahteenmaki P. Sustained-release subdermal estradiol implants: A new alternative in estrogen replacement therapy. Am J Obstet Gynecol 1993; 169: 1248-54
49. Suhonen S P, Allonen H O, Lahteenmaki P. S ustained-release estradiol implants and a levonorgestrel-releasing intrauterine device in hormone replacement therapy. Am J Obstet Gynecol 1995; 172: 562-7
50. A ndersson K, Mattsson L A, Rybo G, Stadberg E. I ntrauterine release of levonorgestrel- A new way of adding progestogen in hormone replacement therapy. Obstet Gynecol 1992; 79: 963-7